Department of Internal Medicine, University of Ulsan College of Medicine, Gangneung Asan Hospital, Gangneung, Republic of Korea.
Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
Digestion. 2020;101(3):279-286. doi: 10.1159/000499424. Epub 2019 May 8.
BACKGROUND/AIMS: Acid suppression therapy is thought to be associated with the topography of Helicobacter pylori and associated gastritis, leading to corpus-predominant gastritis. This study was aimed to investigate the influence of proton pump inhibitor (PPI) treatment on the distribution of H. pylori and associated gastritis in patients with atrophic change.
Patients who underwent endoscopic resection for gastric neoplasms and received PPI for 2 months were prospectively analyzed. Biopsy specimens were obtained from 5 areas in the stomach before, during, and after the treatment with PPI. Histological examination was -performed using the updated Sydney system, and -bacterial density of H. pylori was further graded by immunohistochemistry (ClinicalTrials.gov registration number NCT02449941).
A total of 15 patients were analyzed, of whom 7 had H. pylori infection. The degree of activity and inflammation were greater in patients with H. pylori infection than in those without H. pylori infection. During the PPI treatment, the density of H. pylori decreased not only in the antrum but also in the corpus. The degree of activity and inflammation improved significantly in the antrum, particularly in the presence of H. pylori infection, while the corpus gastritis was not affected by PPI use. Atrophy and intestinal metaplasia remained unchanged in both regions of the stomach. The observed changes reverted following the discontinuation of PPI treatment.
PPI treatment decreased H. pylori both in the antrum and the corpus in patients with atrophic gastritis. Antral gastritis improved during PPI treatment, whereas no changes were found in the corpus.
背景/目的:酸抑制疗法被认为与幽门螺杆菌的分布和相关胃炎有关,导致以胃体为主的胃炎。本研究旨在探讨质子泵抑制剂(PPI)治疗对萎缩性改变患者中幽门螺杆菌和相关胃炎分布的影响。
前瞻性分析了因胃肿瘤而行内镜切除术并接受 PPI 治疗 2 个月的患者。在接受 PPI 治疗前、治疗中和治疗后,从胃的 5 个部位获取活检标本。使用更新的悉尼系统进行组织学检查,并通过免疫组织化学进一步对幽门螺杆菌的细菌密度进行分级(ClinicalTrials.gov 注册号:NCT02449941)。
共分析了 15 例患者,其中 7 例有幽门螺杆菌感染。与无幽门螺杆菌感染的患者相比,有幽门螺杆菌感染的患者的活动度和炎症程度更高。在 PPI 治疗期间,幽门螺杆菌的密度不仅在胃窦部下降,而且在胃体部也下降。胃窦部的活动度和炎症显著改善,尤其是在有幽门螺杆菌感染的情况下,而胃体部胃炎不受 PPI 使用的影响。胃体和胃窦部的萎缩和肠化生均无变化。停止 PPI 治疗后,观察到的变化逆转。
在萎缩性胃炎患者中,PPI 治疗不仅降低了胃窦部的幽门螺杆菌密度,而且降低了胃体部的幽门螺杆菌密度。PPI 治疗期间胃窦炎得到改善,而胃体部无变化。